Physician profile
Arthur Marush
NPI 1003912809
$2,737.44
in general payments reported to CMS, 2019-2025
28 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $281 · 2021: $555 · 2022: $451 · 2023: $355 · 2024: $503 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $362.41 | 2019-2025 | Verquvo, Capvaxive, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $330.34 | 2020-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $243.68 | 2021-2025 | |
| Pfizer INC. | $242.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $237.86 | 2023-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $176.38 | 2019-2021 | |
| Bardy Diagnostics, INC. | $133.23 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $105.51 | 2020-2022 | |
| Esperion Therapeutics, INC. | $93.15 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.59 | 2019-2025 | Jardiance |
| Abbott Laboratories | $88.46 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $83.71 | 2021-2024 | Farxiga, Breztri |
| Sanofi Pasteur INC. | $82.41 | 2020-2025 | |
| Novo Nordisk INC | $64.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $56.69 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $44.80 | 2024-2025 | |
| Shield Therapeutics INC | $41.85 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $36.37 | 2019-2020 | |
| Boston Scientific Corporation | $35.97 | 2024 | Watchman Flx |
| Edwards Lifesciences Corporation | $29.58 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $27.53 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $25.47 | 2025 | Tryngolza |
| Bridgebio Pharma, INC. | $19.90 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $18.39 | 2023 | Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $16.43 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $16.40 | 2024 | |
| Seqirus USA INC | $16.29 | 2024 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $15.46 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Marush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.